Heron Therapeutics (HRTX) Common Equity (2016 - 2025)
Historic Common Equity for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $14.9 million.
- Heron Therapeutics' Common Equity rose 13720.78% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 13720.78%. This contributed to the annual value of -$33.7 million for FY2024, which is 94.78% up from last year.
- Per Heron Therapeutics' latest filing, its Common Equity stood at $14.9 million for Q3 2025, which was up 13720.78% from -$27.3 million recorded in Q2 2025.
- Heron Therapeutics' 5-year Common Equity high stood at $196.2 million for Q1 2021, and its period low was -$40.0 million during Q3 2024.
- In the last 5 years, Heron Therapeutics' Common Equity had a median value of -$21.7 million in 2022 and averaged $15.4 million.
- As far as peak fluctuations go, Heron Therapeutics' Common Equity crashed by 35031.68% in 2023, and later skyrocketed by 13720.78% in 2025.
- Over the past 5 years, Heron Therapeutics' Common Equity (Quarter) stood at $77.6 million in 2021, then tumbled by 82.5% to $13.6 million in 2022, then plummeted by 350.32% to -$34.0 million in 2023, then rose by 0.95% to -$33.7 million in 2024, then soared by 144.23% to $14.9 million in 2025.
- Its Common Equity was $14.9 million in Q3 2025, compared to -$27.3 million in Q2 2025 and -$28.5 million in Q1 2025.